Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the IQVIA Medical Research Data UK database
Authors' conclusion
In this nationwide study, no difference in the incidence of gout was documented in patients treated with SGLT2 inhibitors compared to DPP-4 inhibitor users. This neutral finding remained consistent in sensitivity analyses.
Study context
- Population
- Patients with T2DM, IQVIA Medical Research Data UK database, November 1, 2012 to December 31, 201830,389 person-years
- Participants
- 13,617 vs 29,426
- Exposure
- SGLT2i vs DPP-4i
- SGLT2 inhibitorsn = 13,617
- DPP-4 inhibitorsn = 29,426reference
- Outcome
- Incident gout
Methodological detailsopen cohort, propensity-score matched, new-user design, active comparator
- Open cohort
- Propensity-score matched
- New-user design
- Active comparator
Main finding
As reported in the abstract
Unadjusted hazard ratio
1.18
95% CI 0.76–1.83
By group
Between SGLT2 inhibitors and DPP-4 inhibitors
unadjusted HR 1.18 (95% CI 0.76–1.83)
- Incident gout cases over 30 389 person-years
- 85
Observational data: associations, not effects.
Further findings
Per 1000 person-years
| Outcome | SGLT2i | DPP-4i | aHR (95% CI) | |
|---|---|---|---|---|
| Incident gout, at-treatment analysisAt-treatment analysis | 2.68 | 2.53 | 1.3 (0.90–2.29) | |
| 0.512Adjusted hazard ratio (log scale) |
Sensitivity analyses
- Sensitivity analyses did not change the findings
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the IQVIA Medical Research Data UK database. Diabetes Obes Metab. Published 20 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →